Large Clinical Trial to Evaluate Ambulatory Oxygen Is Feasible in Interstitial Lung Disease
The results of a pilot study have demonstrated feasibility of conducting a large clinical trial in patients with fibrotic interstitial lung disease.
Restrictive Lung Disease
Ofev Approved for Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Pirfenidone Gets Breakthrough Therapy Status for Unclassifiable Interstitial Lung Disease
Pirfenidone is currently marketed as Esbriet for the treatment of idiopathic pulmonary fibrosis in adults.
Interstitial Lung Abnormalities, Disease More Likely in People With HIV
Individuals with HIV were more likely to have interstitial lung abnormalities and findings suspicious for the presence of interstitial lung disease than individuals without HIV.
Thrombomodulin Alfa Not Recommended for Idiopathic Pulmonary Fibrosis
Use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis is not recommended, according to phase 3 clinical trial results.
Idiopathic Pulmonary Fibrosis Annualized Costs Totals More Than $10,000 Per Patient
Patients with idiopathic pulmonary fibrosis are faced with a heavy economic burden, with mean annual costs for admission and inpatient care totaling more than $10,000 per patient.
Idiopathic Pulmonary Fibrosis Susceptibility Identified Via Genomic Markers
Altered expression of 14 genes in adults was associated with idiopathic pulmonary fibrosis susceptibility.
Chronic Viral Infection May Increase Idiopathic Pulmonary Fibrosis Risk
Persistent or chronic, but not acute, viral infections significantly increase the risk of developing idiopathic pulmonary fibrosis.
Greater Circulating Adipokines May Play a Role in Early ILD Pathogenesis
Higher adiponectin levels are associated with lower high attenuation areas, a computed tomography-based measure of subclinical interstitial lung disease.
Obesity Linked to Underutilization of Low Tidal Volume Ventilation in ARDS
ARDS was underrecognized in the study population across all body mass indexesBMIs, but this underrecognition did not explain why patients with class 3 obesity were more likely to meet ARDS criteria but not receive low tidal volume ventilation.
Next post in CHEST 2019
